Wave Life Sciences Ltd. — Q1 2022 Form 10-Q
Business context and period. Clinical-stage genetic medicines company developing stereopure oligonucleotide therapies using its PRISM platform. This summary covers the three months ended March 31, 2022; financial amounts are in U.S. dollars.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Revenue | $1.75 million | Nil |
| Research and development expense | $27.47 million | $33.39 million |
| General and administrative expense | $12.37 million | $10.08 million |
| Operating loss | $38.09 million | $43.47 million |
| Net loss | $37.81 million | $42.46 million |
| Basic and diluted loss per share | $0.62 | $0.86 |
| Cash used in operating activities | $39.87 million | $44.38 million |
Revenue was collaboration revenue, principally for Takeda research and development services; Wave reported no product revenue and expects none for the foreseeable future. The company remains loss-making, so a conventional profit margin is not meaningful. Net loss narrowed by $4.65 million year over year, as lower R&D expense and collaboration revenue more than offset higher G&A and lower other income.
At March 31, cash and cash equivalents were $61.71 million and short-term investments were $50.00 million, totaling $111.71 million; restricted cash was an additional $3.65 million. Management expects available cash, cash equivalents and short-term investments to fund operations for at least 12 months, subject to assumptions that could prove incorrect. Total current assets were $124.38 million and current liabilities were $58.49 million. No interest-bearing debt is reported; liabilities include deferred revenue and operating leases. Shareholders’ equity was a deficit of $0.05 million, versus positive equity of $32.50 million at year-end 2021.
Investing activities used $50.21 million, including a $50.00 million purchase of short-term investments; this largely reflects moving funds into investments, not operating burn. Financing provided $1.32 million, mainly from at-the-market share sales, versus $8.64 million in Q1 2021. The company sold 458,092 shares through its ATM program for net proceeds of $1.2 million in Q1.
Material changes, outlook and risks
- R&D expense fell $5.92 million, mainly from lower spending on discontinued WVE-120101 and WVE-120102 HD programs and lower ALS/FTD program costs. G&A rose $2.30 million, primarily from compensation and professional services.
- Takeda collaboration revenue was $1.6 million in Q1; deferred revenue was $113.0 million at quarter-end, including $36.4 million current. The Category 2 collaboration component had been discontinued by an October 2021 amendment; Category 1 programs remain in effect.
- Management expects significant ongoing R&D and manufacturing spending and may need additional financing. Future equity issuance could dilute shareholders; financing may not be available on acceptable terms. The company reports an accumulated deficit of $843.3 million.
- In April 2022, Wave reported FOCUS-C9 biomarker reductions after single doses of WVE-004, including a 34% reduction in CSF poly(GP) at day 85 in the 30 mg cohort (p=0.011). Some patients had CSF neurofilament light elevations; the limited dataset and follow-up did not establish clinical effects. The company planned additional data during 2022 and an open-label extension around mid-year.
- Wave expected 2022 clinical data from WVE-003 and WVE-N531, and planned to select an AATD AIMer candidate and start IND-enabling toxicology in Q3 2022. These are forward-looking plans, not reported results.
- After quarter-end, a performance-based RSU milestone was achieved: 50% of outstanding units vested, resulting in 384,646 shares issued. Wave expected to record about $3.8 million of related share-based compensation in Q2.
- COVID-19 may continue to affect discovery, clinical trials and supply chains. Clinical, regulatory, intellectual-property, competition and capital-market risks remain material; the filing reports no material legal proceedings.
Investor facts to verify
- Whether the stated 12-month liquidity runway remains supported by operating burn, trial costs and updated cash balances.
- Subsequent clinical data and safety follow-up for WVE-004, WVE-003 and WVE-N531, including the significance of exploratory biomarker findings.
- Takeda collaboration progress, option decisions and the timing of recognition of the remaining deferred revenue.
- Share issuance, ATM utilization and dilution, including the post-quarter RSU vesting and Q2 compensation expense.